A Phase 1 interventional study of ME1100 inhalation solution and ME1100 inhalation solution in Pneumonia, Bacterial, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-05.
Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Pneumonia, Bacterial with a site in United States — none open to participants now, 2 under way, none of them phase 3. Pneumonia, Bacterial · United States.
Among the 50 studies in Pneumonia, Bacterial with a site in United States, this one is the 35th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2015, is one of 4 in phase 1, and was the 27th registered.
153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.
Browse Pneumonia, Bacterial studies →None of the 50 studies in Pneumonia, Bacterial with a site in United States is open now. The open studies under Pneumonia, Bacterial, anywhere →
Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 10 · Phase 4 5
First in 1999; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.
Median enrollment 120 across the 44 interventional studies, 547 across the 6 observational. Of the 46 that completed or were terminated, 23 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 50 have an industry lead sponsor. The 10 most frequent:
Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Meiji Seika Pharma Co., Ltd. has 2 studies filed under Pneumonia, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 50 studies in Pneumonia, Bacterial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP). The secondary objective of this study is to assess the safety and tolerability of ME1100 for the treatment of subjects with MVBP to assess the safety and tolerability of ME1100.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following inclusion criteria in order to be eligible for the study:
Has a known or suspected mechanically ventilated bacterial pneumonia with at least 1 of the following:
Plus at least 2 of the following:
Exclusion Criteria:
Participants who meet any of the following exclusion criteria will not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ME1100 inhalation solution
Drug: ME1100 inhalation solution
Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Also known as: Arbekacin inhalation solution
High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Also known as: Arbekacin inhalation solution
Arbekacin concentrations in respiratory fluids collected via bronchoalveolar lavage (BAL) for epithelial lining fluid (ELF)
Time frame: Day 3
Plasma arbekacin concentrations
Time frame: Day 1 to Day 5
Urinary elimination of arbekacin
Time frame: Day 2
Arbekacin concentrations in tracheal aspirate
Time frame: Day 2
Number of participants with adverse events
Time frame: Screening through 14 days after the end of treatment
The record gives a start of Sep 2015, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arbekacin
Meiji Seika Pharma Co., Ltd.